Malaysia pneumonia
treatment drugs market is anticipated to witness a steady CAGR in the forecast
period, 2024-2028. The pneumonia treatment drugs market in Malaysia has
witnessed significant growth over the past few years, owing to the rise in elderly population in the country. Malaysia is experiencing a
demographic shift with an aging population. The increasing trend of longevity
has caused the proportion of the elderly population to rise significantly in
recent years. According to the United Nations Population Fund (UNFPA), the
elderly population in Malaysia, aged 60 years and above, will increase from 3.2
million in 2020 to 5.3 million by 2030.
The main factor
behind the rise in the geriatric population in Malaysia is the country's
successful public health policies and the advancements in medical technology.
Improved healthcare services have enabled individuals to live longer, and the
life expectancy of Malaysians has increased from 60 years in the 1960s to over
74 years currently. This trend is also accompanied by a decrease in the birth
rate (the birth rate for Malaysia in 2023 was reported to be 15.873 births
per 1000 people, which is a decline of 1.2% from 2022), which affects the
number of young generation in the country, further contributing to the increase
in the proportion of elderly individuals.
The rising
geriatric population presents significant challenges to the country's health
and social care systems. The elderly population has a higher risk of developing
chronic diseases such as cardiovascular diseases (cardiovascular disease
cases increase by 5% every year in Malaysia), and diabetes (the diabetes
prevalence in Malaysia ranges from 7.3% to 23.8%, according to published
reports) as well as some air borne infections like pneumonia, COVID-19, and
asthma (the prevalence of asthma in Malaysia has risen from 6.4% to 9.4% in
children aged 6-7 years and from 9% to 13% in children aged 13-14 years), among
others. All these problems require complex healthcare services. As a result,
the demand for medical and social care services will inevitably increase,
putting significant pressure on the already overburdened healthcare system. The
aging population also poses economic challenges, as fewer people are in the
workforce to support the needs of the elderly.
To address the
challenges posed by the rising geriatric population, the Malaysian government
has implemented various measures. One such measure is the establishment of the
National Policy for the Elderly, which aims to address the challenges faced by
the elderly population. The policy focuses on enhancing the well-being and
quality of life of the elderly, providing healthcare services, and promoting
social and economic participation.
Another
solution to the challenges posed by the aging population is the development of
age-friendly communities. An age-friendly community is a place where older
adults can live safely, enjoy good health, and participate in community
activities. The concept involves developing accessible housing, transportation,
and health services that cater to the needs of the elderly population. By
creating age-friendly communities, the elderly population can remain active and
participate in the workforce, contributing to the economy while enjoying a good
quality of life.
Increasing Prevalence of Pneumonia in Malaysia
Pneumonia is a serious respiratory infection that affects millions of
people around the world. In Malaysia, the prevalence of pneumonia has been on
the rise in recent years, causing concern for healthcare professionals and
policymakers alike.
Pneumonia is an infection of the lungs that can be caused by bacteria,
viruses, or fungi. It is a serious illness that can lead to hospitalization,
complications, and even death, particularly in vulnerable populations such as
the elderly, young children, and people with weakened immune systems. According
to a report by the Ministry of Health Malaysia, pneumonia was one of the top 10
leading causes of hospitalization in 2019.
There are several factors driving the increasing prevalence of pneumonia
in Malaysia. Firstly, the country has experienced a rise in air pollution
levels in recent years, which can exacerbate respiratory infections and
increase the risk of developing pneumonia. In addition, changes in weather
patterns, including fluctuations in temperature and humidity, can also
contribute to the development of pneumonia.
Secondly, lifestyle factors such as smoking and poor nutrition can
weaken the immune system, making individuals more susceptible to infections
such as pneumonia. Malaysia has one of the highest smoking rates in Southeast
Asia, and poor nutrition is also a concern in some populations.
Thirdly, Malaysia's aging population is a significant factor
contributing to the increasing prevalence of pneumonia. As people age, their
immune systems weaken, making them more susceptible to respiratory infections
such as pneumonia. According to the Department of Statistics Malaysia, the
proportion of Malaysians aged 65 years and above is expected to increase from
5.5% in 2020 to 15.3% in 2040.
The increasing prevalence of pneumonia in Malaysia has significant
implications for public health. Pneumonia can lead to hospitalization,
complications, and even death, particularly in vulnerable populations. The rise
in pneumonia cases also places a burden on the healthcare system, leading to
increased healthcare costs and resource utilization.
Therefore, the surge in pneumonia prevalence in the nation is likely to
propel the growth of Malaysia pneumonia treatment drugs market.
COVID-19
Associated Pneumonia in Malaysia
COVID-19,
the respiratory illness caused by the novel coronavirus, was declared a global
pandemic by the World Health Organization (WHO) in March 2020. COVID-19 can
lead to pneumonia, a serious respiratory infection that can cause severe
illness and death. Malaysia, like many other countries, has seen a significant
number of COVID-19 cases since the pandemic began, with many of these cases
associated with pneumonia.
COVID-19
associated pneumonia occurs when the virus infects the lungs and causes inflammation
and damage to the respiratory system. This can lead to pneumonia, a condition
in which the lungs become inflamed and filled with fluid, making it difficult
to breathe. COVID-19 pneumonia can be particularly dangerous in vulnerable
populations such as the elderly, people with pre-existing medical conditions,
and those with weakened immune systems.
The
symptoms of COVID-19 associated pneumonia can vary, but typically include
fever, cough, difficulty breathing, and fatigue. In severe cases, patients may also
experience chest pain, confusion, and bluish lips or face. People who suspect
they have COVID-19 associated pneumonia should seek medical attention
immediately to receive a proper diagnosis and treatment.
Treatment
for COVID-19 associated pneumonia in Malaysia typically involves supportive
care, such as oxygen therapy and medications to manage the symptoms. Patients
may also receive antiviral drugs or other medications to help fight the virus
and prevent complications. In severe cases, hospitalization may be necessary,
with treatment options including mechanical ventilation or extracorporeal
membrane oxygenation (ECMO) to support breathing.
The
Malaysian government has implemented various measures to combat the spread of
COVID-19 and reduce the incidence of associated pneumonia. These measures
include social distancing, wearing face masks in public places, and
restrictions on travel and public gatherings. The government has also provided
funding and resources to support the healthcare system in managing COVID-19
cases and associated pneumonia.
Growing
Number of Hospital-Acquired Pneumonia Infections in Malaysia
Hospital-acquired
pneumonia (HAP) is a serious and potentially life-threatening infection that
occurs when a patient develops pneumonia during their hospital stay. HAP can be
caused by a variety of bacteria, viruses, and other pathogens, and it is a
growing concern in Malaysia.
HAP
is a significant issue in Malaysia due to several factors, including the
prevalence of antibiotic-resistant bacteria and the high number of patients
admitted to hospitals. Patients who are in the hospital for extended periods,
those who are on ventilators, and those with weakened immune systems are
particularly susceptible to HAP. Additionally, HAP is more prevalent in
patients who have undergone surgery or who have other underlying medical
conditions.
The
symptoms of HAP can be like those of community-acquired pneumonia, including
coughing, fever, chills, shortness of breath, and chest pain. However, patients
with HAP may also experience confusion, fatigue, and a decline in overall
health. HAP is a serious and potentially life-threatening condition, and prompt
diagnosis and treatment are essential to reduce the risk of complications.
The
treatment for HAP typically involves antibiotics, oxygen therapy, and other
supportive measures to manage symptoms and prevent complications. In some
cases, patients may require hospitalization or transfer to an intensive care
unit for more intensive treatment.
Download Free Sample Report
Market
Segmentation
Malaysia pneumonia treatment drugs market
can be segmented by drugs, drug class, distribution channel, and region. Based
on drugs, the market can be divided into branded, and generics. Based on drug
class, the market can be segmented into antibacterial drugs, antiviral drugs,
antifungal drugs, and others. Based on distribution channel, the market can be
fragmented into hospital pharmacies, retail pharmacies, and online pharmacies.
Market Players
GlaxoSmithkline Pharmaceutical Sdn. Bhd.,
Pfizer (Malaysia) Sdn Bhd, Sanofi-Aventis (Malaysia) Sdn. Bhd., Astrazeneca
Sdn. Bhd., Roche (Malaysia) Sdn. Bhd., Bayer Co. (Malaysia) Sdn Bhd, and Cipla
Malaysia Sdn Bhd are some of the leading players operating in the Malaysia pneumonia
treatment drugs market.
|
Attribute
|
Details
|
|
Base
Year
|
2022
|
|
Historic
Data
|
2018 – 2021
|
|
Estimated
Year
|
2023
|
|
Forecast
Period
|
2024 – 2028
|
|
Quantitative
Units
|
Revenue in USD Million and CAGR for 2018-2022 and 2023-2028
|
|
Report
Coverage
|
Revenue
forecast, company share, competitive landscape, growth factors, and trends
|
|
Segments
Covered
|
By Drugs
By Drug Class
By Distribution
Channel
By Region
|
|
Regional
Scope
|
West
and East
|
|
Key
Companies Profiled
|
GlaxoSmithkline Pharmaceutical Sdn. Bhd., Pfizer
(Malaysia) Sdn Bhd, Sanofi-Aventis (Malaysia) Sdn. Bhd., Astrazeneca Sdn.
Bhd., Roche (Malaysia) Sdn. Bhd., Bayer Co. (Malaysia) Sdn Bhd, and Cipla
Malaysia Sdn Bhd
|
|
Customization
Scope
|
10%
free report customization with purchase. Addition or alteration to country,
regional & segment scope.
|
|
Pricing
and Purchase Options
|
Avail customized purchase options to meet your exact research
needs. Explore purchase options
|
|
Delivery
Format
|
PDF and Excel through Email (We can also provide the editable
version of the report in PPT/Word format on special request)
|
Report Scope:
In this report, the Malaysia pneumonia
treatment drugs market has been segmented into following categories, in
addition to the industry trends which have also been detailed below:
·
Malaysia
Pneumonia Treatment Drugs Market, By Drugs:
o
Branded
o
Generics
·
Malaysia
Pneumonia Treatment Drugs Market, By Drug Class:
o
Antibacterial Drugs
o
Antiviral Drugs
o
Antifungal
Drugs
o
Others
·
Malaysia
Pneumonia Treatment Drugs Market, By Distribution Channel:
o
Hospital Pharmacies
o
Retail Pharmacies
o
Online
Pharmacies
·
Malaysia Pneumonia
Treatment Drugs Market, By Region:
o West
o East
Competitive Landscape
Company
Profiles: Detailed
analysis of the major companies present in the Malaysia pneumonia treatment
drugs Market.
Available Customizations:
With the given market data, TechSci
Research offers customizations according to a company’s specific needs. The
following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to
five).
Malaysia pneumonia treatment drugs Market is an upcoming report to be released
soon. If you wish an early delivery of this report or want to confirm the date
of release, please contact us at [email protected]